The effect of interventions targeting gut microbiota on depressive symptoms: a systematic review

Abstract

Background: Despite their popularity, the efficacy of interventions targeting gut microbiota to improve depressive symptoms is unknown. Our objective is to summarize the effect of microbiome-targeting interventions on depressive symptoms.

Methods: We conducted a systematic review and meta-analysis. We searched MEDLINE, Embase, PsycINFO, Database of Abstracts of Reviews of Effects, Cochrane Database of Systematic Reviews and the Cochrane Controlled Register of Trials from inception to Mar. 5, 2021. We included studies that evaluated probiotic, prebiotic, synbiotic, paraprobiotic or fecal microbiota transplant interventions in an adult population (age ≥ 18 yr) with an inactive or placebo comparator (defined by the absence of active intervention). Studies must have measured depressive symptoms with a validated scale, and used a randomized controlled trial study design. We conducted a random effects meta-analysis of change scores, using standardized mean difference as the measure of effect.

Results: Sixty-two studies formed the final data set, with 50 included in the meta-analysis. Probiotic, prebiotic, and synbiotic interventions on depressive symptoms showed statistically significant benefits. In the single studies evaluating each of fecal microbiota transplant and paraprobiotic interventions, neither showed a statistically significant benefit.

Interpretation: Despite promising findings of benefit of probiotic, prebiotic and symbiotic interventions for depressive symptoms in study populations, there is not yet strong enough evidence to favour inclusion of these interventions in treatment guidelines for depression. Critical questions about species administered, dosage and timing relative to other antidepressant medications remain to be answered.

View Publication

Share the Post:
Receive the latest news

Join Our Journey

Be the First to Know: Unlock exclusive updates on the progress and launch timeline of our groundbreaking biotherapeutics product development.

Name(Required)

Asem Bala

MSc

Asem Bala, MSc has over 20 years of experience in Healthcare & Clinical Research Management, now working at Taylored Biotherapeutics to create partnerships and ensure regulatory approvals.

Dr. Valerie Taylor

MD, PhD, FRCP

Dr. Valerie Taylor, MD, PhD, FRCP is a Professor of Psychiatry at the University of Calgary. She completed a Bachelor of Medical Science and graduated from medical school at Memorial University of Newfoundland. She subsequently finished her residency training in Psychiatry and got her PhD in Neuroscience from McMaster University in Hamilton, Ontario. Prior to coming to Calgary, she was the chief of Psychiatry at the Women’s College Hospital and the chief of Adult Health Services at the Center for Addiction and Mental Health in Toronto.

Her academic focus has been on the area of medical psychiatry – specifically, for the last 5 years, on the gut brain axis and the the gut microbiome. She is the only funded researcher in North America examining the therapeutic effects of fecal transplant as a treatment for mental health and she currently has 4 novel clinical trials looking at modifying the gut microbiome to treat mood disorders as well as the largest biological neuroscience microbiome repository in North America. She has over 180 peer reviewed publications and funding from a variety of national and international funding agencies. In 2020 she started Taylored Biotherapeutics, a micro therapeutics drug company. Today her primary role is in leading product development, getting regulatory approval, and finding partnerships.